S&P 500 7,708 -0.52% Nasdaq 26,331 -0.97% Dow Jones 53,463 -0.57% FTSE 100 10,743 -0.83% DAX 26,091 -0.91% Nikkei 225 65,326 -4.37% Hang Seng 25,495 +0.22% WTI Crude 84.24 +2.23% Gold 4,567 +4.26% US 10-Year Treasury Yield 4.653 +0.26% S&P 500 7,708 -0.52% Nasdaq 26,331 -0.97% Dow Jones 53,463 -0.57% FTSE 100 10,743 -0.83% DAX 26,091 -0.91% Nikkei 225 65,326 -4.37% Hang Seng 25,495 +0.22% WTI Crude 84.24 +2.23% Gold 4,567 +4.26% US 10-Year Treasury Yield 4.653 +0.26%

LATEST

OpenAI 'will be a public company in 2027' or sooner, CFO Friar tells employees●Chams makes N7.7 billion from cards, biometrics services as H1 profit rises●Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rally●Trump calls for passage of a key cryptocurrency bill as it falters in the Senate: ‘We need Congress to take the next step’●Argentina Beef Consumption Falls to Its Lowest in Over Two Decades●Bank of America makes bullish call on 77-year-old healthcare stock●Webull Corporation Q2 2026 Earnings: Recap of $BULL Earnings Call & Forecast●BILL Holdings Inc. Q4 2026 Earnings: Recap of $BILL Earnings Call & Forecast●OpenAI 'will be a public company in 2027' or sooner, CFO Friar tells employees●Chams makes N7.7 billion from cards, biometrics services as H1 profit rises●Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rally●Trump calls for passage of a key cryptocurrency bill as it falters in the Senate: ‘We need Congress to take the next step’●Argentina Beef Consumption Falls to Its Lowest in Over Two Decades●Bank of America makes bullish call on 77-year-old healthcare stock●Webull Corporation Q2 2026 Earnings: Recap of $BULL Earnings Call & Forecast●BILL Holdings Inc. Q4 2026 Earnings: Recap of $BILL Earnings Call & Forecast●

Front Page

Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

fm-term-meta-233910339-mutual-fund | FORTUNE · 2h ago

Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

Read the full story at fm-term-meta-233910339-mutual-fund | FORTUNE →

More Front Page

Where we stand on Broadcom after Marvell muscles in on its key customer Google

US Top News and Analysis · 1h ago

US long-term borrowing costs ease after government steps in

BBC News · 1h ago

Fortune 500 companies got billions in tariff refunds. Here's who's giving customers a cut—and who isn't

fm-term-meta-233910339-mutual-fund | FORTUNE · 1h ago

American Airlines is finally bringing back seatback screens after nearly 10 years in a premium push to win back customers

fm-term-meta-233910339-mutual-fund | FORTUNE · 2h ago